Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 5/20 | 0.45 |
| ▸ | JAK2 | O60674 | 4/20 | 0.45 |
| ▸ | KARS1 | Q15046 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | AXL | P30530 | 2/20 | 0.39 |
| ▸ | IDH2 | P48735 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | SIK1 | P57059 | 2/20 | 0.38 |
| ▸ | SIK2 | Q9H0K1 | 2/20 | 0.38 |
| ▸ | SIK3 | Q9Y2K2 | 2/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.38 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30086588 | 1.00 | JAK3 (0.45) | JAK3JAK2KARS1EGFRAXL | |
| SCHEMBL30086398 | 0.88 | ACVR1 (0.49) | JAK3JAK2KARS1EGFRCDK2 | |
| SCHEMBL30086450 | 0.88 | JAK2 (0.51) | JAK3JAK2EGFRSYKCDK2 | |
| SCHEMBL23906917 | 0.88 | JAK2 (0.51) | JAK3JAK2EGFRSYKCDK2 | |
| SCHEMBL23906562 | 0.88 | ACVR1 (0.49) | JAK3JAK2KARS1EGFRCDK2 | |
| SCHEMBL25263747 | 0.86 | JAK2 (0.50) | JAK3JAK2KARS1EGFRACVR1 | |
| SCHEMBL30086905 | 0.86 | JAK2 (0.50) | JAK3JAK2KARS1EGFRACVR1 | |
| SCHEMBL25269932 | 0.82 | JAK2 (0.46) | JAK3JAK2KARS1EGFRCDK2 | |
| SCHEMBL30086540 | 0.82 | JAK2 (0.46) | JAK3JAK2KARS1EGFRCDK2 | |
| SCHEMBL25222695 | 0.80 | IGF1R (0.46) | JAK3JAK2EGFRSYKIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-11673879-B2 | Substituted pyrimidines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673879-B2 | Substituted pyrimidines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673879-B2 | Substituted pyrimidines and methods of use | ALK, TYMP, ENTPD5 | JAK3 1474/4885JAK2 1187/4885KARS1 1073/4885 |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | ALK, TYMP, ENTPD5 | JAK3 1474/4885JAK2 1187/4885KARS1 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.